Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1997-10-16
|
| pubmed:abstractText |
To substantiate the reported sensitivity of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) to St Jude-type multiagent chemotherapy and to identify means of selecting patients most likely to benefit from such treatment, we analyzed the clinical and biologic characteristics of 12 patients with classic Ph+ ALL who were treated in either of two total therapy programs at St Jude Children's Research Hospital (1989-1994). Event-free survival estimates for this cohort were compared with historical data on 11 patients from an earlier total therapy study (Lancet 1994; 343: 331-332). The prognostic importance of age, white blood cell count and other presenting features was assessed by the logrank test in all 23 patients. Complete remissions were induced in 92% of the patients treated since 1989, compared with 82% of the historical control group (P > 0.05). There was essentially no difference in event-free survival between the study group and historical controls (4-year Kaplan-Meier estimates, 33 +/- 19% s.e. vs 36 +/- 13%). Further analysis of potentially informative risk factors identified a good-prognosis subgroup defined by an initial white blood cell count of < or =25 x 10(9)/l and a 4-year event-free survival of 73 +/- 19%. In conclusion, intensive multiagent chemotherapy offers an attractive therapeutic option for children and adolescents with Ph+ ALL and low presenting leukocyte count.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1493-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9305603-Adolescent,
pubmed-meshheading:9305603-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9305603-Child,
pubmed-meshheading:9305603-Child, Preschool,
pubmed-meshheading:9305603-Chromosome Aberrations,
pubmed-meshheading:9305603-Chromosome Disorders,
pubmed-meshheading:9305603-Combined Modality Therapy,
pubmed-meshheading:9305603-Disease-Free Survival,
pubmed-meshheading:9305603-Female,
pubmed-meshheading:9305603-Humans,
pubmed-meshheading:9305603-Immunophenotyping,
pubmed-meshheading:9305603-Karyotyping,
pubmed-meshheading:9305603-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:9305603-Leukocyte Count,
pubmed-meshheading:9305603-Male,
pubmed-meshheading:9305603-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:9305603-Survival Analysis
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts.
|
| pubmed:affiliation |
Department of Hematology-Oncology, St Jude Children's Research Hospital, and the University of Tennessee, Memphis, College of Medicine, 38105, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|